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Major depression disorder (MDD) is an important public health 
issue (Dowlati et al., 2010; Miller et al., 2009), predicted to be 
the second leading cause of disability by the year of 2020 
behind only ischemic heart disease (Rush et al., 2004). MDD is 
the most commonly diagnosed psychiatric disorder in adults 
over 60 years of age (Dowlati et al., 2010). The Diagnostic and 
Statistical Manual of Mental Disorders (DSM-V) describes 
that for the diagnosis of MDD, five or more symptoms have to 
be present during a 2-week period and represent a change from 
previous functioning; at least one of the symptoms should be 
either: (i) depressive mood or (ii) loss of interest or pleasure 
for the major part of the day. The other symptoms that may be 
present are significant weight loss or weight gain, insomnia or 
hypersomnia, fatigue or loss of energy, diminished ability to 
concentrate or indecisiveness, recurrent thoughts of death and 
suicidal ideation or attempt (American Psychiatric Association, 
2013). Not only the high incidence of MDD and the disability 
associated with the disease, but also the high rate of inadequate 
treatment of the disorder remains a serious concern (Kessler 
et al., 2003). It is estimated that 30–50% of the patients do not 
respond to treatment with antidepressants (Bschor et al., 2012) 
due to either lack of efficacy or intolerable side effects (Rush 
et al., 2006). Another possible reason for the ineffectual treat-
ment of MDD has been the incomplete understanding of the 
nature of depression (Friedman, 2014). The high rate of treat-
ment resistance, together with the high suicide risk in unrespon-
sive patients and the overwhelming economic costs to society 
constitute the basis of the search for new therapeutic agents 
(Brunello et al., 2006), aiming to improve the quality of life or 
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even cure these patients. Remission, that is, (virtual) absence 
of symptoms should be the objective of MDD treatment, since 
it is related to better functioning and a better prognosis than a 
response without remission (Rush et al., 2006; Trivedi et al., 
2006).
Even though information concerning the epidemiology, 
symptoms and complications of mood disorders are well docu-
mented, the etiology and pathophysiology of depression are not 
completely elucidated (Rosenblat et al., 2014). The monoamine 
depletion hypothesis has historically dominated the view on the 
pathophysiology of depression. It suggests that an imbalance, 
mainly in serotonergic and noradrenergic neurotransmission is 
the core of the pathophysiology of depression (Massart et al., 
2012; Prins et al., 2011). However, the lack of responsiveness to 
conventional treatment with antidepressants and high rates of 
treatment resistance suggests that additional mechanisms might 
play a role in depression. Over the last 20 years, psychiatric 
research has provided support for the hypothesis that inflamma-
tory processes and brain–immune interactions are involved in the 
pathogenesis of MDD and may contribute to the serotonergic and 
noradrenergic dysfunction (Song and Wang, 2011). Stimuli like 
inflammation, chronic stress and infection can trigger the activa-
tion of microglia, the brain’s immune cells, to release pro-inflam-
matory cytokines that can act on two pathways that may lead to 
MDD and neurodegeneration, such as: (1) activation of the hypo-
thalamic–pituitary adrenal axis, generating an imbalance in the 
serotonergic and noradrenergic circuits; (2) increased activity 
of the enzyme indoleamine-2,3-deoxygenase (IDO), resulting 
mainly in depletion of serotonin. Considering that MDD is a very 
complex and heterogeneous disorder, it is possible that immune 
deregulation is not present in all depressed patients, but only in 
specific sub-populations (Vogelzangs et al., 2012). Evidence also 
shows that lack of therapeutic benefit of antidepressants might be 
associated with persistent immunological impairment (Carvalho 
et al., 2013).
In this review, we aim to discuss the potential role of anti-
inflammatory treatment in MDD. We first address the most 
relevant immunological mechanisms by which increased levels 
of pro-inflammatory cytokines may lead to MDD, highlighting 
the hypothalamic–pituitary–adrenal (HPA) axis hyperactiva-
tion and the indoleamine-2,3-dioxygenase (IDO) pathway. 
Next, we summarize the most recent studies concerning mono-
therapy with non-steroidal anti-inflammatory drugs (NSAIDs) 
in MDD patients, discuss the anti-inflammatory effects of 
standard antidepressant drugs and augmentative strategies with 
NSAIDs.
The hypothesis of immunological 
involvement in the pathophysiology 
of major depressive disorder (MDD)
An exhaustive discussion on all the possible immunological 
pathways that might play a role in the pathophysiology of depres-
sion is out of the scope of this article. Before focusing on the 
possible anti-inflammatory treatment for depression, however, 
we would like to review key points and molecular markers that 
are most relevant for the anti-inflammatory therapeutic strategies 
further discussed.
Association between pro-inflammatory 
cytokines and depression: the role of 
microglia
The hypothesis of a causal relationship between pro-inflamma-
tory cytokines and depression was first described by Smith et al. 
in 1991, in the macrophage theory of depression. The theory was 
based on observations that cytokines produced by macrophages, 
when given to healthy volunteers, induced symptoms of depres-
sion and had brain effects that included the activation of the HPA 
axis (Dantzer et al., 2011; Smith, 1991). Afterwards, Maes et al. 
corroborated the theory by collecting biochemical evidence for 
the immunological activation in depressed patients (Maes et al., 
1995, 1997). In response to infection or inflammatory conditions, 
peripherally produced cytokines can act on the brain and cause 
behavioral symptoms (Dantzer et al., 2008), such as malaise, 
prostration, fatigue, numbness and anorexia (Frick et al., 2013). 
The main elucidated pathways to which pro-inflammatory 
cytokines can reach the brain include: (1) cytokine passage 
through leaky regions in the blood–brain barrier (BBB); (2) 
active transport via saturable transport molecules; (3) activation 
of endothelial cells and other cell types (including perivascular 
macrophages) lining the cerebral vasculature (which in turn pro-
duce cytokines and other inflammatory mediators); (4) binding to 
cytokine receptors associated with peripheral afferent nerve fib-
ers (e.g. vagus nerve), delivering cytokine signals to relevant 
brain regions including the nucleus of the solitary tract and hypo-
thalamus (Dantzer et al., 2008; Miller et al., 2009). The nuclear 
factor NF-κB has been identified as an essential mediator at the 
blood–brain interface that communicates peripheral inflamma-
tory signals to the central nervous system (CNS). Production of 
inflammatory cytokines can also be induced directly within the 
brain, via stress or other processes (e.g. vascular insults in late 
life depression) (Miller et al., 2009; Nadjar et al., 2005).
In the CNS, microglia cells are the main cellular regulators of 
the innate immune response to both physiological and pathologi-
cal conditions (Czeh et al., 2011). They transform from an 
immunesurveillant into an activated state in response to patho-
gens and to synaptic and neuronal injury in several neurological 
disorders. During their activation, microglia change from a rami-
fied to a hyper-ramified (Pace et al., 2006; Rawdin et al., 2013; 
Zunszain et al., 2011) phenotype and subsequently adopt an 
amoeboid morphology, a mechanism which has been suggested 
to help microglia to invade lesions (Raivich, 2005). This activa-
tion can be acute or chronic, depending on the type of stimulus 
(inflammation, stress, infection, neuronal injury) and its duration 
(Czeh et al., 2011). Thus, activation of microglia in stress might 
be different from microglial activation during inflammation or 
infection (Sugama et al., 2009). When chronically activated, 
microglia can produce a wide variety of neurotoxins such as pro-
inflammatory cytokines, free radicals, nitric oxide, chemokines, 
proteinases and eicosanoids (Venneti et al., 2013) that may cause 
neuronal dysfunction and aggravate underlying pathologies 
(Venneti et al., 2006). As such, activated microglia can be a trig-
gering factor for mood disorders (Rosenblat et al., 2014). 
Activated microglia have already been found in the brain of 
stress-induced animal models of depression (Wohleb et al., 2011, 
2012), however the data that would confirm the presence of acti-
vated microglia in humans are still limited (Kreisel et al., 2014). 
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Evidence for neuroinflammation in MDD could be obtained non-
invasively by positron emission tomography (PET) using radioli-
gands that bind to the translocator protein (TSPO), a receptor that 
is upregulated in the mitochondria of activated microglia cells 
(Doorduin et al., 2008). Recently, the presence of neuroinflam-
mation in depressed patients during a major depressive episode 
was demonstrated using PET with the TSPO radioligand [18F]
FEPPA (Setiawan et al., 2015). The study was conducted on 20 
patients in a major depressive episode secondary to MDD that 
were medication free for at least 6 weeks, and 20 healthy con-
trols. A significant increase in the uptake of the tracer was found 
in the prefrontal cortex, anterior cingulated cortex and insula, 
indicating the presence of activated microglia in these brain 
regions. Moreover, PET tracer uptake (microglia activation) was 
correlated with the Hamilton Depression Rating Scale (HDRS) 
score (Hamilton, 1960) in the anterior cingulated cortex 
(Setiawan et al., 2015). Hannestad et al. (2013) also conducted a 
study to evaluate the presence of neuroinflammation in patients 
with mild-to-moderate depression using [11C]PBR28, another 
TSPO ligand. No difference between patients and controls was 
found in this study (Hannestad et al., 2013). This could be due to 
the small sample size (n = 10) and the fact that patients with signs 
of peripheral immune activation (as defined by elevated high-
sensitive C-reactive protein, hsCRP) were excluded. Further 
studies with PET imaging should be conducted in order to cor-
roborate or not the presence of activated microglia in MDD in a 
non-invasive manner. Thus, an increased density of activated 
microglia was observed post mortem in the anterior midcingulate 
cortex, dorsolateral prefrontal cortex and mediodorsal thalamus 
of suicidal patients with affective disorders (Steiner et al., 2008).
More recently, an increased gut permeability or ‘leaky gut’ 
theory was described as a possible contributor to the peripheral 
and central production of pro-inflammatory cytokines by micro-
glia in a subgroup of depressed patients. The investigated sub-
jects were diagnosed with MDD and presented specific symptoms 
which have been correlated to increased levels of IgM and IgA to 
lipopolysaccharide (LPS) of enterobacteria in chronic fatigue 
syndrome (Maes et al., 2007). The observed symptoms were 
pain, muscular tension, fatigue, concentration difficulties, failing 
memory, irritability, stress and irritable bowel, among others. In 
summary, depressed patients demonstrated elevated serum IgM 
and IgA levels against LPS of gram-negative enterobacteria, as 
compared with healthy controls. Increased IgM and IgA levels 
indicate an increased gut permeability, allowing invasive entero-
bacteria to cause a systemic and central inflammation (Maes 
et al., 2008; Slyepchenko et al., 2017).
Elevated pro-inflammatory cytokines and 
hypothalamic–pituitary–adrenal (HPA) 
dysfunction in major depressive disorder
Numerous studies have indicated that MDD is accompanied by 
elevated levels of inflammatory biomarkers, such as the pro-
inflammatory cytokines interleukin (IL)-1β, IL-6, IL-18, tumor 
necrosis factor alpha (TNF-α), interferon-gamma (INF-γ) 
(Alboni et al., 2010; Dowlati et al., 2010; Hasler, 2010; Krogh 
et al., 2014; Loftis et al., 2010; Maes, 2011; Messay et al., 2012; 
Najjar et al., 2013; Pace and Miller, 2009; Raison and Miller, 
2011; Rawdin et al., 2013; Steiner et al., 2011; Sukoff Rizzo 
et al., 2012; Zunszain et al., 2011) and the acute phase proteins 
such as C-reactive protein (CRP) (Jokela et al., 2015; Valkanova 
et al., 2013) Munzer et al. (2013) even suggested that, besides, 
for example, stress hormones and psychopathological measures, 
cytokines may serve as biomarkers for individualized treatment 
of depression (Munzer et al., 2013). Thus, animal studies have 
shown that systemic exposure to inflammatory challenges, such 
as LPS, not only causes a systemic inflammation but also induces 
a central inflammatory response in the brain, which is reflected 
by activation of microglia (Qin et al., 2007).
The pro-inflammatory cytokines produced during activation 
of microglia might have an effect on central serotonin levels and 
affect the HPA axis (Figure 1). The immune and neuroendocrine 
systems act together in order to restore and maintain physiologi-
cal homeostasis during inflammation and other harmful stimuli 
that might induce systemic cytokine production (Beishuizen and 
Thijs, 2003). Therefore, it has been suggested that abnormalities 
in the HPA axis might play a key role in the development and 
recurrence of depression. Increased cytokine production may 
contribute to the development of depression directly via activa-
tion of the HPA axis or indirectly through cytokine-induced glu-
cocorticoid receptor resistance (Anders et al., 2013). The release 
of TNF-α and IL-6 increases the production of corticotrophin-
releasing hormone, adrenocorticotropic hormone and cortisol by 
acting directly on hypothalamic and pituitary cells (Dowlati 
et al., 2010). Cytokines might also increase glucocorticoid recep-
tor resistance through several signaling pathways, including acti-
vation of the p38 mitogen-activated protein kinase (MAPK) and 
by stimulating changes in the expression of glucocorticoid recep-
tors (Anders et al., 2013; Pace et al., 2007). The high levels of 
circulating stress hormones in the CNS might affect the neuro-
transmitter homeostasis, the neuronal growth factor synthesis 
and ultimately, disturb the functioning of neuronal circuits of the 
limbic system (Guloksuz et al., 2014). HPA hyperactivity has 
been associated with the pathophysiology of suicidal behavior, 
excessive activity of the noradrenergic system and dysfunction of 
the serotonergic system (Kim et al., 2008; Steiner et al., 2008).
Pro-inflammatory cytokine effects on 
neurotransmitter metabolism
The link between pro-inflammatory cytokines and decreased 
serotonergic synthesis has already been extensively explored. It 
was hypothesized that during inflammation, pro-inflammatory 
cytokines such as IL-1β, IL-2, IL-6, INF-γ and TNF-α (Anderson 
et al., 2013; Kim et al., 2012; Myint and Kim, 2003) increase the 
activity of IDO and reduce the production of serotonin. IDO cata-
lyzes tryptophan (TRP) catabolism through the kynurenine path-
way (Dobos et al., 2012; Myint, 2012; Myint et al., 2013), 
producing kynurenic acid (KYN), quinolinic acid (QUIN) and 
nicotinamide adenine dinucleotide (NAD+) (Guillemin, 2012; 
Zunszain et al., 2011). Substantial evidence demonstrates that a 
pro-inflammatory scenario leads to increased and unbalanced 
production of tryptophan catabolites (TRYCATs) that play a 
major role in the development and maintenance of MDD. A 
recent meta-analysis by Ogawa and colleagues (2014) demon-
strated convincing evidence for lowered plasma TRP levels in 
patients with MDD. The study included MDD patients (n = 744) 
and healthy controls (n = 793), and found a highly significant 
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decreased levels of TRP in depressed patients vs controls (p < 
0.001). A secondary analysis using only data of unmedicated 
MDD patients (n = 156) and controls (n = 203) demonstrated an 
even more pronounced difference in TRP levels in unmedicated 
patients, when compared with controls (p < 0.001). These data 
suggest that psychotropic therapy (antidepressants, antipsychot-
ics and benzodiazepines) reduced the difference in TRP levels 
between groups (Ogawa et al., 2014). Decreased levels of TRP 
and consequent depletion of serotonin results in the development 
of depressive symptoms, as proposed by the classic monoamine 
depletion hypothesis. IDO induction may have evolved as a 
mechanism for the maintenance of NAD+, which is the final 
product of the IDO and TRP catabolism pathway. NAD+ is 
important for the induction of sirtuins, which contribute to many 
of the processes that are deregulated in depression including neu-
rogenesis, circadian rhythms and mitochondrial regulation 
(Anderson et al., 2013). Despite the evidence that suggest a role 
of TRYCATs in depression, one should keep in mind that 
TRYCATs have also been associated with the psycho-somatic 
symptoms that accompany depression. Since depression and 
somatization shared common pathways, it may be difficult to dis-
criminate between these effects (Maes and Rief, 2012).
QUIN, a product formed in the TRYCAT pathway, is an endog-
enous N-methyl-D-aspartate (NMDA) receptor agonist, while 
KYN is an NMDA antagonist. QUIN is a neurotoxin and responsi-
ble for the generation of reactive oxygen and nitrogen species 
(ROS and RNS, respectively). A disrupted balance between KYN 
and QUIN production is observed in the neurotoxicity associated 
with several inflammatory brain diseases such as Alzheimer’s dis-
ease, Parkinson’s disease and major psychiatric disorders. 
Activated microglia and infiltrating macrophages are the major 
source of QUIN in the brain and it is involved in the deleterious 
pathophysiological cascade within the CNS (Guillemin, 2012). An 
aberrant NMDA receptor stimulation associated with pro-inflam-
matory cytokines may suppress brain-derived neurotrophic factor 
translation, neurogenesis, provoke changes in brain volume, along 
with dendritic atrophy and synaptic loss (Savitz et al., 2015; 
Swardfager et al., 2016). The atrophy of the hippocampus in 
patients with MDD has been demonstrated, not only by imaging 
techniques such as magnetic resonance imaging (MRI) but also in 
post mortem studies (Stockmeier et al., 2004). QUIN also increases 
glutamate release to neurotoxic levels, inducing oxidative and 
nitrosative stress (O&NS) in MDD (Slyepchenko et al., 2016). 
O&NS damages lipids, proteins and the DNA, as demonstrated 
through lipid peroxidation, DNA strand breaks, increased protein 
carbonyl formation and disruption of mitochondrial function 
(Bryleva and Brundin, 2017; Morris et al., 2017). Inflammatory 
responses are often accompanied by O&NS, as reviewed in detail 
by Maes et al. (Maes et al., 2011). Under normal conditions, the 
level of ROS are balanced by an antioxidant defense system. 
However, when there is an unbalanced condition between oxidants 
and antioxidants, a state of oxidative stress is achieved. Recently, a 
meta-analysis confirmed the association between depression and 
oxidative stress, measured mainly in plasma or serum of depressed 
patients and healthy controls (Palta et al., 2014). It is also known 
that lower levels of antioxidants, such as co-enzyme Q10, 
Figure 1. Hypothesis of immune involvement in the pathophysiology of major depressive disorder. Inflammatory, infectious and stressful 
challenges might trigger the activation of the resident microglia. Activated microglia produce pro-inflammatory cytokines that can contribute to 
neurodegeneration and depressive disorders through the hyper-activation of the HPA axis and the increase in indoleamine-2,3-dioxygenase (IDO) 
enzyme activity. Hyper-activation of the HPA axis leads to the increase of corticotrophin-releasing hormone (CRH), adrenocorticotropic hormone 
(ACTH) and cortisol that disturb neurotransmitter homeostasis (mainly noradrenergic and serotonergic systems) and the neuronal growth factor 
synthesis. IDO decreases the synthesis of serotonin by switching the balance between the production of serotonin from tryptophan and the 
production of kynurenic acid (KYN) and quinolinic acid (QUIN). Depletion of serotonin leads to depressive symptoms. QUIN acts as a neurotoxin, 
gliotoxin, pro-inflammatory mediator and can also alter the integrity of the blood–brain barrier (BBB).
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glutathione, ascorbic acid, vitamin E, zinc and polyunsaturated 
fatty acids are regularly detected in the blood of depressed patients 
(Maes et al., 2011; Slyepchenko et al., 2016), supporting the notion 
of an oxidative-stress state in this population.
Other potential harmful effects of inflammatory cytokines on 
neurotransmitter function are due to the disruption of tetrahydro-
biopterin (BH4). BH4 is an essential enzyme co-factor for pheny-
lalanine hydroxylase, tryptophan hydroxylase and tyrosine 
hydroxylase which are rate-limiting enzymes for the synthesis of 
serotonin, dopamine and norepinephrine, respectively (Miller 
et al., 2013). Moreover, BH4 is also an enzyme co-factor for the 
conversion of arginine to nitric oxide (NO) through nitric oxide 
synthase (NOS) (Haroon et al., 2012). Inflammatory cytokines 
stimulate the production of NO, increasing the utilization of BH4 
and thus decreasing neurotransmitter synthesis (Miller et al., 
2013).
TNF-α is a specific pro-inflammatory cytokine that has 
received attention as a potential modulator of the serotonin trans-
porter (SERT or 5-HTT) and consequently 5-HT uptake and 
brain availability. The first study to demonstrate in vitro the 
capacity of TNF-α to increase the expression of SERT in mouse 
brain cell lines was conducted in 2006 (Zhu et al., 2006). 
Afterwards, another study showed that prolonged in vitro treat-
ment with TNF-α enhances SERT expression and activity in both 
glial and neuronal cells, suggesting that the p38 MAPK pathway 
could be involved (Malynn et al., 2013). Therefore, it was 
hypothesized that under conditions of chronic inflammation, 
increased levels of pro-inflammatory cytokines such as TNF-α 
would enhance SERT-mediated 5-HT uptake and significantly 
impact the available extracellular 5-HT. Since astrocytes rapidly 
degrade 5-HT following uptake, enhanced astrocyte uptake 
might affect the turnover rate of this neurotransmitter, resulting 
in decreased total brain 5-HT (Malynn et al., 2013). In a proof-of-
concept study conducted by Cavanagh et al. (2010), six patients 
with rheumatoid arthritis were treated with adalimumab (a TNF-
α inhibitor) and tested the hypothesis that TNF-α blockade 
would alter SERT activity in the brain of the patients, through 
single photon emission tomography (SPECT). In addition, 
depressive severity was evaluated through the HDRS. SPECT 
scans were conducted 14 days before the start of the treatment 
and repeated 4 days after the last treatment. There was a signifi-
cant decrease in SERT density (p = 0.03), with five of the patients 
exhibiting a 20% decrease. Depressive scores improved in all 
subjects. This represents one of the first in vivo studies suggest-
ing the link between TNF-α blockade and SERT modulation 
(Cavanagh et al., 2010)
All the aforementioned pathways have detrimental effects in 
clinical depression and additionally play a role in chronic depres-
sion. Pro-inflammatory cytokines, TRYCATs and O&NS together 
may contribute to a state called neuroprogression, related to neu-
rodegeneration, reduced neurogenesis, neural plasticity and 
apoptosis (Maes et al., 2012).
Major depressive disorder as a comorbidity 
to pro-inflammatory medical conditions: 
circumstantial evidence
Several inflammatory diseases have also been associated with 
higher risks of development of depression and this might provide 
further clues for our understanding of the underlying mechanism 
of MDD. Patients with a myocardial infarction (MI), for example, 
have a prevalence of depressive disorder that is about three times 
higher than in the general population (Liu et al., 2013). MI trig-
gers an inflammatory cascade that leads to increased pro-inflam-
matory cytokines in plasma. These cytokines can be transported 
across the blood–brain barrier and promote the activation of 
microglia (Rana et al., 2010). Conventional antidepressants gen-
erally have limited effect in MI patients (Liu et al., 2013), proba-
bly due to the presence of neuroinflammation as a result of the 
chronic elevated immune profile. Autoimmune diseases such as 
systemic lupus erythematosus, rheumatoid arthritis and multiple 
sclerosis are also associated with a higher prevalence of depres-
sion. The association might be explained by two hypotheses: (1) 
chronic stress derived from long-term use of corticosteroids 
impairs corticosteroid-receptor signaling, therefore, the severe 
clinical condition and the inadequate adaptation to stress cause 
persistent hyper-secretion of stress hormones; (2) persistent eleva-
tion of pro-inflammatory cytokines due to the chronic inflamma-
tion leading to neuroinflammation through the aforementioned 
pathways (Postal and Appenzeller, 2015). Obesity has also been 
linked to the development of depression via the elevated inflam-
matory profile associated with the disorder (Pan et al., 2012). This 
relation might be partially explained by the fact that adipocytes in 
the white adipose tissue secrete cytokines, mainly IL-6 and TNF-
α, that are referred to as adipocytokines (Shelton and Miller, 
2010). The secretion of the pro-inflammatory markers might lead 
to an immune activation and be a risk factor for the development 
of MDD. In fact, this theory has been supported by a meta-analy-
sis conducted by Luppino et al. (2010) showing a clear bidirec-
tional association between depression and obesity: obese people 
have a 55% increased risk of developing depression over time, 
while depressed people had a 58% increased risk of becoming 
obese. Depression’s causal role in obesity might be due to neu-
roendocrine disturbances, through a long-term activation of the 
HPA axis and release of cortisol, along with an unhealthy lifestyle 
(Luppino et al., 2010).
In summary, there are circumstantial evidences that links 
(neuro)inflammation to MDD, in particular: (1) microglia activa-
tion that occurs in a number of neuropsychiatric conditions (Frick 
et al., 2013); (2) pro-inflammatory conditions like obesity, MI and 
autoimmune diseases that are often accompanied by depression 
(Raison, 2014); (3) presence of neuroinflammation during a major 
depressive episode in MDD patients visualized through PET 
imaging (Setiawan et al., 2015); (4) significant microgliosis in 
depressed patients that committed suicide (Steiner et al., 2008); 
(5) elevated profile of pro-inflammatory cytokines in the blood of 
depressed patients as compared with controls (Howren et al., 
2009); (6) development of ‘depressive-like behavior’ in rodents 
systemically exposed to inflammatory conditions, exhibiting ele-
vated levels of activated microglia (Wohleb et al., 2012, 2014).
Anti-inflammatory treatment for 
major depressive disorder with non-
steroidal anti-inflammatory drugs
Cyclooxygenases in neuroinflammation: pre-
clinical studies
As previously discussed, MDD appears to be associated with 
elevation of pro-inflammatory cytokines both in peripheral blood 
and the brain, at least in a subpopulation of the patients. These 
pro-inflammatory cytokines can trigger an inflammatory cascade 
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in the brain, which includes the induction of cyclooxygenases 
(COXs) that are key enzymes in the production of prostaglandins 
(Harden et al., 2015). Based on this observation, one could 
hypothesize that treatments targeting the enzymes cyclooxyge-
nase-1 (COX-1) and cyclooxygenase-2 (COX-2) could have a 
beneficial effect in the subgroup of depressed patients with ele-
vated levels of pro-inflammatory cytokines. Indeed, elevated 
COX-2 messenger ribonucleic acid (mRNA) expression was 
found for the first time in peripheral blood of patients with recur-
rent depressive disorder by Gałecki et al. (2012) (Gałecki et al., 
2012). Both COX isoforms catalyze the same reactions: oxida-
tion of arachidonic acid (AA) to yield prostaglandin G2 (PGG2), 
followed by a peroxidase reaction which converts PGG2 to pros-
taglandin H2 (PGH2). In these reactions, reactive oxygen species 
are also produced that can cause severe cell damage. PGH2 is 
transformed into PGE2, PGF2α, PGD2, PGI2 and TXB2 by spe-
cific terminal synthases (Aïd and Bosetti, 2011). PGE2 is the 
main prostaglandin implicated in the inflammatory response, 
pain, fever and autonomic functions (Blais et al., 2005). 
Furthermore, COX-1 and COX-2 are both expressed in the brain. 
COX-2 is detected in synaptic dendrites and excitatory terminals, 
mainly in cortex, hippocampus and amygdala, whereas COX-1 is 
expressed by microglia and perivascular cells (Maes, 2012).
COX-1 has been shown to support the inflammatory process 
and facilitate pro-inflammatory upregulation of prostaglandins in 
animal models of neuroinflammation (Aïd and Bosetti, 2011). 
Indeed, Choi et al. (2008) demonstrated that mice deficient of 
COX-1 showed less neuron degeneration, less microglia activa-
tion and lower expression of pro-inflammatory cytokines and 
PGE2 after exposure to LPS via lateral ventricle injection than 
wild-type mice. Likewise, inhibition of COX-1 with SC-560 
(COX-1 selective inhibitor) showed similar effects as the genetic 
deletion of COX-1 (Choi et al., 2008).
In contrast to COX-1, COX-2 can have either a neurotoxic or 
anti-inflammatory role depending on inflammatory stimuli. 
Results of pre-clinical studies, mainly with celecoxib (a COX-2 
selective inhibitor) treatment are contradictory. In a model of 
chronic unpredictable stress in rats, celecoxib treatment was 
administered for 21 days. The depressive behavior in the stressed 
rats was reversed by the NSAID and PGE2 concentrations 
decreased relative to untreated controls (Guo et al., 2009). 
Another well-known rat model of depression, olfactory bulbec-
tomy (OBX), was used to evaluate the antidepressant effect of 
celecoxib treatment for 14 days. Behavioral alterations of OBX 
rats were reversed by the drug, whereas pro-inflammatory 
cytokines IL-1 and TNF-α levels in the pre-frontal cortex and 
hypothalamus decreased, probably by reduction of systemic 
PGE2 synthesis (Myint et al., 2007). Also, the hypothesis that 
aging contributes to behavioral impairment and increases in the 
pro-inflammatory markers in the hippocampus was tested by 
Casolini et al (2002), using rats aged 12- and 24-months old. 
Chronic treatment with celecoxib for 4 months reduced the levels 
of IL-1β, TNF-α and PGE2 in the hippocampus, and lower corti-
costerone levels in the 12-month-old rats (beginning of the aging 
process). This experiment also demonstrated a possibility for 
improvement of cognitive impairment and the inflammatory state 
at the beginning of the aging process (Casolini et al., 2002). 
However, COX-2 might have also a neuroprotective function in 
response to an inflammatory challenge. Genetic deletion of 
COX-2 enhanced the vulnerability towards an LPS challenge, 
resulting in increased neuronal damage in the hippocampus, 
increased activation of scavenger receptor A mRNA (specific 
marker for phagocytic microglia) and increased the expression of 
TNF-α, IL-6 and IL-1β, as compared with wild-type mice. 
Furthermore, inhibition of COX-2 by chronic administration of 
celecoxib for 6 weeks caused an increase in IL-1β levels in the 
brain of wild-type mice exposed to LPS, as compared with non-
treated LPS-exposed mice (Aid et al., 2008).
Taken together, these data suggest that the enzyme COX-1 
mainly has a pro-inflammatory role in the brain, whereas COX-2 
could be involved in both pro- and anti-inflammatory responses. 
Interestingly, curative treatment with COX-2 selective inhibitors 
in (neuro)inflammatory animal models have shown mostly ben-
eficial outcomes by decreasing inflammatory markers in the 
brain and reversing behavioral alterations, suggesting that there 
might be a possible application for patients with depression and 
elevated pro-inflammatory profile (data summarized in Table 1). 
Also, attenuating the pro-inflammatory role of COX-1 seems to 
be a good strategy to avoid activation of microglia and the sup-
port for the neuroinflammatory process. Further animal studies 
with selective COX-1 inhibitors still need to be conducted in 
order to obtain a better understanding of their role in neuroin-
flammation and putative therapeutic implications.
NSAID monotherapy for major depressive 
disorder: clinical studies
NSAIDs demonstrated promising results in clinical trials for 
depression, mainly involving patients with inflammatory disease 
comorbidities. In patients with osteoarthritis, depression is 2–3 
times more prevalent than in age-matched controls (Iyengar 
et al., 2013). In a study including pooled data from five rand-
omized, multicenter, double-blind, placebo-controlled trials on 
1497 patients with osteoarthritis, subjects were screened for 
MDD with the standard patient health questionnaire-9 (PHQ-9) 
and were divided into three treatment groups: ibuprofen/nap-
roxen (non-selective COX inhibitors), placebo or celecoxib, 
administered for a duration of 6 weeks. Both groups using 
NSAIDs (ibuprofen/naproxen or celecoxib) showed a trend 
towards a reduction in depressive symptoms in patients with 
osteoarthritis, based on the PHQ-9 scores (Iyengar et al., 2013). 
A possible limitation of this study that might have affected the 
results was the celecoxib dosage. The recommended therapeutic 
dose is 400 mg/day, while the patients included in this study 
received only 200 mg/day.
A study that evaluated the efficacy of anti-inflammatory treat-
ment for depressive symptoms alleviation not linked to inflam-
matory comorbidities demonstrated that it might not have any 
beneficial effect. An investigation of the therapeutic benefits of 
COX inhibitors in late-life depression was performed in 2528 
participants over 70-years old with or without significant depres-
sive symptoms, which were screened and randomized to receive 
celecoxib, naproxen or placebo for 12 months. Only 449 patients 
were considered depressed at baseline according to their score on 
the Geriatric Depression Scale (GDS). After the treatment with 
either drug, the GDS score was not reduced (Fields et al., 2012). 
Even though the sample size of this study was big and the treat-
ment period was long, a critical measure of the inflammatory 
markers was not performed. Thus, it is conceivable that some of 
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the patients included in this study might not have an elevated 
immune profile and therefore, would not have any benefit from 
the therapy with NSAIDs.
An epidemiological study called ‘The Health in Men Study’ 
published two papers regarding the usage of aspirin in older men 
(aged 69–87 years old) as prevention for the development of 
depression. The first study evaluated 5556 patients, of which 
4461 (89.9%) had a cardiovascular disease. A 5-year follow up 
revealed that aspirin did not reduce the odds of developing 
depression in late life. One possible explanation is that aspirin 
might lead to greater medical complications due to bleeding, 
increasing the risk of small cerebrovascular lesions that contrib-
ute to a higher incidence of depression (Almeida et al., 2010). 
The second study evaluated a sample of 3687 patients to access 
the relationship of high plasma homocysteine (tHcy), which is 
associated with higher risk of cardiovascular events, and the 
onset of depression. The study confirmed that high tHcy is asso-
ciated with an increased risk of depression, with an odds ratio 
(OR) of 1.80 (95% confidence interval (CI) = 1.39–2.35) and that 
the usage of aspirin is associated with a decrease in the risk of 
depression among these patients, with an OR of 0.60 (95% CI = 
0.20–1.79) (Almeida et al., 2012). Another study in 345 female 
subjects evaluated the risk of developing depression in relation to 
the usage of aspirin during a 10-year follow-up. Estimated rates 
of MDD were 1.7 (95% CI = 0.4–6.9) per 1000 person-years for 
subjects using aspirin and 12.2 (95% CI = 7.9–19.0) per 1.000 
person-years for the non-users. This study suggests that exposure 
to aspirin seems to be associated with a reduced risk of develop-
ing MDD (Pasco et al., 2010).
As summarized in Table 2, available data from a limited 
number of studies suggest that curative treatment of MDD with 
NSAIDs can have a beneficial effect on the relief of depressive 
symptoms, whereas data on the preventive treatment with COX 
inhibitors are still inconclusive. A meta-analysis conducted by 
Köhler et al. (2014) demonstrated that monotherapy treatment 
with celecoxib had borderline significance in the relief of 
depressive symptoms (Köhler et al., 2014). Future clinical rand-
omized clinical trials using NSAID treatment monotherapy 
should be better structured, including only patients with elevated 
levels of inflammatory markers in the blood or cerebral spinal 
fluid (CSF) in combination with questionnaires for scoring 
depressive symptoms. NSAID monotherapy should not be 
encouraged in the absence of inflammation and neither used as 
replacement of conventional antidepressants. Moreover, a better 
description of adverse effects in the studies is paramount. An 
advantage of anti-inflammatory treatment strategies is that 
definitive readouts of target engagement are available. Since the 
majority of anti-inflammatory therapies have an effect on 
inflammatory markers, it can be easily determined through 
blood/plasma samples if the treatment is indeed acting on the 
desired target (Miller and Raison, 2015) and terminated as soon 
as the inflammation is resolved. Complementary diagnostic 
tools such as brain imaging of inflammatory biomarkers (e.g. 
TSPO) through PET would be desirable, since the relationship 
between central and peripheral inflammation in MDD is still 
understudied. Only when the effects on both depressive scores 
and inflammatory markers are known, a clear conclusion can be 
reached about the link between inflammation reduction and 
depression alleviation. Treatment with NSAIDs in a subgroup of 
patients with low depressive symptoms and immune deregula-
tion/inflammatory comorbidities (Köhler et al., 2014) seems to 
be the best approach for future research. Nevertheless, indis-
criminate use of anti-inflammatory treatments for MDD patients 
without inflammation might be harmful, since inflammatory 
cytokines play a pivotal role in learning and memory, as well as 
in neural integrity, neurogenesis and synaptic pruning (Yirmiya 
and Goshen, 2011). Thus, a maximum safe treatment length is 
yet to be established.
Table 1. Summary of results obtained in pre-clinical studies applying NSAID treatment in (neuro)inflammation models. The table presents the 
animal model used, number of subjects (n), duration of treatment, NSAID (selectivity), type of treatment (preventive or curative) and final outcome 
(beneficial/not beneficial).
Authors Animal model n Duration NSAID (selectivity) Type of treatment Outcome
Aid et al. [2008] LPS stereotactic injection in 
the brain of mice
Not described 42 days Celecoxib (COX-2 selective) Preventive Not beneficial
Blais et al. [2005] LPS i.p. injection in mice 86 30 min SC-560 (COX-1 selective); 
NS-398 (COX-2 selective); 
ketorolac and indomethacin 
(COX non-selective)
Preventive Not beneficial 
for all 
treatments
Casolini et al. [2002] Aging rats (12 and 18 months) 60 4 months Celecoxib (COX-2 selective) Preventive Beneficial
Choi et al. [2008] LPS stereotactic injection in 
the brain of mice
Not described 7 days SC-560 (COX-1 selective) Preventive Beneficial
Guo et al. [2009] Chronic unpredictable stress 
in rats
70 21 days Celecoxib (COX-2 selective) Curative Beneficial
Myint et al. [2007] Olfactory bulbectomized model 
of depression in rats
32 14 days Celecoxib (COX-2 selective) Curative Beneficial
Scali et al. [2003] Quisqualic acid injection into 
the nucleus basalis in the 
brain of rats
Not described 7 days Rofecoxib (COX-2 selective) Curative Beneficial
Kurhe et al. [2014] High-fat diet: obesity in mice 36 28 days Celecoxib (COX-2 selective) Curative Beneficial
COX, cyclooxygenase; i.p., intraperitoneal injection; LPS, lipopolysaccharide; NSAID, non-steroidal anti-inflammatory drug; NS-398, COX-2 selective inhibitor; SC-560, 
COX-1 selective inhibitor.
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Side effects of non-steroidal anti-
inflammatory drugs
Considering the possible beneficial aspects of NSAID treatment 
for depression, one should be aware of the possible side effects. 
In a review by Funk and FitzGerald (2007), COX-2 inhibition 
was associated with an increased susceptibility to thrombosis, 
hypertension and atherosclerosis due to a thrombotic effect by 
inhibition of prostacyclins derived from endothelial COX-2 
(Funk and FitzGerald, 2007; Schjerning Olsen et al., 2013). A 
meta-analysis conducted by Kearney et al. (2006) extracted data 
from randomized controlled trials regarding the risk of vascular 
events associated with the usage of selective COX-2 inhibitors vs 
placebo, and vs traditional NSAIDs (n = 145,373). In the com-
parison between selective COX-2 inhibitors vs placebo, a 42% 
higher incidence of vascular events occurred in COX-2 users as 
compared with placebo. A twofold increase in MI was also 
observed. When evaluating stroke incidence, no difference 
between groups was found. Importantly, 121 trials were long-
term trials (mean of 139 weeks) while 112 were short-term trials 
(mean of 11 weeks). Two thirds of vascular events occurred in 
nine long-term trials; therefore, the hazards of cardiovascular 
events emerged after a year to 18 months of selective COX-2 
inhibitors’ chronic usage. With regard to selective COX-2 inhibi-
tors vs traditional NSAIDs, no significant difference was found 
regarding the risk of vascular events (Kearney et al., 2006). The 
increased risk of vascular events might be due to an increased 
Th1 immune response (pro-inflammatory) when selective COX-2 
inhibitors are chronically used. This hypothesis was based on the 
atherosclerotic plaques scenario, where selective COX-2 inhibi-
tors might provoke macrophage accumulation at the inflamed 
arterial endothelial site. This response leads to increased produc-
tion of pro-atherogenic cytokines, attracting lymphocytes and 
macrophages that will exacerbate the inflammation, increase 
plaque instability and vulnerability to rupture, embolization and 
consequent MI (Padol and Hunt, 2010). Still, this immunological 
modulation is a slow process, occurring after 12 months of 
chronic therapy (Kearney et al., 2006; Padol and Hunt, 2010). 
This possible mixed anti-inflammatory and pro-inflammatory 
effect of COX-2 deserves consideration before chronic usage rec-
ommendation in clinical practice (Scher and Pillinger, 2009).
Additionally, NSAIDs are well recognized for causing peptic 
ulceration and ulcer complications. Cohort studies have esti-
mated that the total risk of hospitalization for gastrointestinal 
complications associated with NSAID use are between 1.3 and 
2.2 events per 1000 patients. Protective strategies as co-prescrip-
tion of a protective drug such as misoprostol or a proton pump 
inhibitor can be applied to reduce those events (Hawkey, 2003). 
Selective COX-2 inhibitors present an advantage in this matter as 
the incidence of clinically significant ulcers were reduced by 
54% and ulcer complications by 57%, as compared with non-
selective NSAIDs (Bombardier et al., 2000).
In summary, if the inflammatory hypothesis for MDD is con-
firmed, the implication would be that anti-inflammatory strate-
gies might hold promise for the treatment of depressed patients 
with chronically elevated inflammatory biomarkers or inflamma-
tory comorbidities. The effectiveness of the treatment must be 
followed by measurements of peripheral inflammatory biomark-
ers associated with depressive scores and the obtained data 
should be used to determine the required treatment length. 
Nonetheless, NSAIDs are far from being a panacea for depres-
sion and might benefit only a subgroup of depressed patients.
The anti-inflammatory effect of 
antidepressants
Effect of antidepressants on cytokine levels
Although antidepressants have been used in therapy for depres-
sion for more than 50 years, the mechanism of action of most of 
Table 2. Résumé of the outcome of clinical studies relating the usage of non-steroidal anti-inflammatory drug (NSAID) and depression. The table 
shows the number of subjects (n), type of subjects, duration of treatment/prevention, NSAID (selectivity), type of treatment (preventive/curative) 
and final outcome (beneficial/not beneficial).
Authors n Subjects Duration NSAID (selectivity) Type of treatment Outcome
Almeida et al. 
[2010]
5556 Aged men (69–87) with 
cardiovascular disease
5 years Aspirin (COX non-
selective)
Preventive Not beneficial
Almeida et al. 
[2012]
3687 Aged men (69–87) with 
high levels of plasma 
homocysteine
5 years Aspirin (COX non-
selective)
Preventive Beneficial
Fields et al. [2012] 2312 Depressive (449); healthy 
(2079); aged 70+
12 months Celecoxib (COX-2 
selective); naproxen 
(COX non-selective)
Preventive Not beneficial for 
both treatments
Pasco et al. [2010] 345 22 MDD and 323 controls 10 years Aspirin (COX non-
selective)
Preventive Beneficial
Chen et al. [2010] 1 case report Depressed patient 5 years Celecoxib (COX-2 
selective)
Curative Beneficial
Iyengar et al. [2013] 1497 Osteoarthritis patients 6 weeks Celecoxib (COX-2 
selective); ibuprofen 
or naproxen (COX 
non-selective)
Curative Beneficial for all 
treatments
COX, cyclooxygenase; MDD, major depressive disorder; NSAID, non-steroidal anti-inflammatory drug.
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these drugs still remains a mystery. Antidepressant drugs usually 
act on the monoaminergic systems, although they can have dif-
ferent mechanisms of action. Some antidepressant drugs were 
also found to elicit anti-inflammatory and neuroprotective 
effects, which might be partly due to their influence on cytokine 
production (Obuchowicz et al., 2014). The influence on the 
cytokine production might be related to antidepressant action on 
cyclic adenosyl monophosphate (cAMP), serotonin metabolism, 
the HPA axis or through a direct action on neurogenesis (Taraz 
et al., 2013).
The silencing of over-activated glia by antidepressants could 
stop neuroinflammation and may therefore be beneficial not only 
for MDD, but also for other CNS diseases. The effects of antide-
pressant drugs on cytokine levels have been investigated in vitro 
in cell cultures. A recently published study by Obuchowicz et al. 
(2014) evaluated the anti-inflammatory effects of imipramine, a 
tricyclic antidepressant (TCA), and fluoxetine, a selective seroto-
nin reuptake inhibitor (SSRI), on IL-6, IL-1β and TNF-α secre-
tion by primary mixed glial cultures stimulated with LPS. Even 
though both drugs were able to decrease the levels of the pro-
inflammatory cytokines, only imipramine prevented morpholog-
ical changes and activation of microglia (Obuchowicz et al. 
2014). In another study, Xia et al. (1996) tested the inhibitory 
effect of the antidepressants imipramine, clomipramine (TCAs) 
and citalopram (SSRI) on the release of the pro-inflammatory 
cytokines IL-1β, IL-6 and TNF-α by stimulated human lympho-
cytes and monocytes. All antidepressants exerted inhibitory 
effects on cytokine release and also increased the levels of cAMP 
(Xia et al. 1996). In another in vitro study, clomipramine, sertra-
line (SSRI) and trazodone (heterocyclic antidepressant) were 
able to decrease IFN-γ levels and increase the production of the 
anti-inflammatory cytokine IL-10 (Maes et al., 1999). Using the 
same methodology, Maes et al. (2005) found that fluoxetine 
(SSRI) also has immunomodulatory effects on the secretion of 
cytokines, such as TNF-α and IFN-γ (Maes et al., 2005). 
Nonetheless, conflicting results have been published by Munzer 
et al. (2013), who tested the effect of escitalopram (an SSRI), 
citalopram and mirtrazapine (serotonin and noradrenaline reup-
take inhibitors, SNRIs) on the secretion levels of cytokines IL-1β, 
IL-2, IL-4, IL-6, IL-17, IL-22 and TNF-α in stimulated whole 
blood of 15 depressed patients ex vivo. A T cell (OKT3) and a B 
cell (5C3) stimulant was used in the whole blood to induce 
cytokine production in vitro. Curiously, citalopram increased the 
levels of IL-1β, IL-6, TNF-α, and IL-22, whereas mirtrazapine 
increased IL-1β, TNF-α and IL-22 and escitalopram decreased 
IL-17. The differences in cytokine production levels might be 
due to distinctive therapeutic effects between the drugs (Munzer 
et al., 2013).
Pre-clinical studies have yielded interesting results for antide-
pressants that decrease cytokine levels, mainly TCAs and SSRIs. 
Alboni et al. (2013) demonstrated promising effects with imipra-
mine and fluoxetine. Both imipramine and fluoxetine were able 
to reduce the levels of IFN-γ, IL-6 and increase the expression of 
the anti-inflammatory cytokine IL-4 in the hypothalamus of 
healthy male Sprague-Dawley rats after a 28-day treatment 
(Alboni et al., 2013). Moreover, imipramine was also able to 
decrease mRNA levels for IL-6 in brain microglia in a rat model 
of social defeat, which was accompanied by a reversal in social 
avoidance behavior (Ramirez et al., 2015). In a model of MI, rats 
were either treated with saline or escitalopram for 2 weeks. 
Plasma levels of IL-1β, TNF-α and PGE2 were significantly 
decreased after treatment (Bah et al., 2011).
Several studies have explored the anti-inflammatory effect of 
antidepressants in clinical studies, as summarized in Table 3. The 
class of antidepressants that was mostly tested was the SSRI, fol-
lowed by TCA and SNRI. Most studies showed anti-inflammatory 
effects of antidepressants. For instance, Brunoni et al. (2014) 
recently published the results of a trial with 103 depressed patients 
treated with sertraline for 6 weeks. The levels of IL-2, IL-4, IL-6, 
IL-10, IL-17, IFN-γ were found to be significantly decreased after 
the treatment (Brunoni et al., 2014). ‘The Netherlands Study of 
Depression and Anxiety’ evaluated IL-6 and TNF-α levels in 
depressed patients and found that SSRIs were able to decrease 
IL-6 levels, but not TNF-α (Vogelzangs et al., 2012). The effect 
on IL-6 is in agreement with other studies published (Basterzi 
et al., 2005; Hannestad et al., 2011; Sluzewska et al., 1995; Taraz 
et al., 2013; Yoshimura et al., 2009). Summarizing, SSRIs have an 
effect on cytokine levels, mainly on IL-6, TNF-α and IL-1β. On 
the other hand, when evaluating the effects of venlafaxine (SNRI) 
on TNF-α and IL-1β in 12 MDD patients after 8 weeks of treat-
ment, the HDRS score decreased at least 50% compared with 
baseline, whereas no decrease was observed in pro-inflammatory 
cytokine levels. (Piletz et al., 2009). This might be due to two fac-
tors: the length of the study was too short to observe any effects on 
cytokine levels, or because of the known pro-inflammatory effect 
of norepinephrine on innate immune cells (Thayer and Sternberg, 
2010). However, the small number of patients completing the trial 
(n = 12) might be a major limitation of the study. The authors 
mentioned that the power analysis performed revealed that an n = 
12 would be sufficient to detect an antidepressant-induced effect 
on pro-inflammatory cytokines assuming the agent would act as 
an SSRI as reported by Leo et al. (2006). SSRIs and SNRIs have 
different mechanisms of action, and therefore the same antide-
pressant-induced effect on pro-inflammatory cytokines should not 
be expected. Also, the sample size of the study of Leo et al. (2006) 
was of 46 MDD patients and 46 age-matched healthy controls. 
Therefore, the obtained data by Piletz et al. (2009) should be 
interpreted with care. The limited duration of the treatment with 
antidepressant drugs applied and the small number of subjects 
evaluated seem to be general limitations of the studies published 
until now.
Even though promising results were obtained in vitro and in 
pre-clinical studies with TCAs, limited clinical trials have been 
performed with this class of antidepressant. Tousoulis et al. 
(2009) conducted a clinical study in 154 patients that suffered 
from heart failure and developed MDD. A total of 120 patients 
received an SSRI and 34 patients were treated with a TCA/SNRI. 
The ones that were treated with TCA/SNRI had lower levels of 
TNF-α and CRP compared with the SSRI group (Tousoulis et al., 
2009). The underlying mechanism of action that can explain how 
TCAs affect pro-inflammatory cytokines is largely unknown. It 
is hypothesized that antidepressants (mainly SSRIs and TCA) 
decrease pro-inflammatory cytokines levels through the cAMP 
pathway (Figure 2). 5-HT (5-hydroxytryptamine or serotonin) 
increases intracellular cAMP levels via G protein-coupled sero-
tonin receptors that can stimulate adenylyl cyclase, which results 
in inhibition of the protein kinase A pathway and a reduction in 
the expression of cytokines (Xia et al. 1996). For imipramine in 
particular, the effect might be explained by the down-regulation 
of microglial activation (Ramirez et al., 2015).
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Possible biomarkers for major depressive 
disorder: can we predict response to therapy?
As already suggested, pro-inflammatory cytokines, such as 
IL-1β, IL-6 and TNF-α, could be useful biomarkers for investi-
gating the presence or level of inflammation during MDD 
screening. Moreover, studies have demonstrated that the levels 
of pre-treatment biomarkers can be useful predictors of treat-
ment response.
Lanquillon et al. (2000), performed a study in 24 MDD patients 
and 15 controls, using a 6-week treatment protocol with amitripty-
line (TCA) and evaluating immunological parameters such as IL-6 
and TNF- α in whole blood. After the treatment period, patients 
were classified as responders and non-responders according to 
HAM-D scale. Patients who responded to treatment had signifi-
cantly lower levels of IL-6 than controls (p < 0.05) or non-respond-
ers (p < 0.05) on baseline measurements. Moreover, regardless of 
treatment outcome, IL-6 levels in both responders and non-
responders returned to control levels after 6 weeks of treatment. 
TNF-α levels were elevated in responders and non-responders at 
baseline, as compared with controls (p < 0.01). After treatment, the 
decrease in TNF-α levels was only significant in the responder 
group (p < 0.05). The data suggest that IL-6 levels can predict 
response to therapy, whereas TNF-α paralleled the clinical 
response (Lanquillon et al., 2000). Another study conducted by 
O’Brien et al. (2007) investigated the differences in the levels of 
IL-6, IL-8, IL-10, soluble IL-6 receptor (which may act as an ago-
nist of IL-6) and TNF-α between depressive patients who were 
SSRI-treatment resistant, former SSRI-treatment-resistant patients 
that are now euthymic due to therapy change and healthy controls. 
The depressed patients who were SSRI non-responders had 
marked activation of pro-inflammatory cytokines with high levels 
of IL-6 and TNF-α. Currently euthymic patients with a prior his-
tory of SSRI resistance had pro-inflammatory cytokine levels 
similar to healthy subjects (O’Brien et al., 2007). Eller et al. (2008) 
also found that higher levels of TNF-α are predictive for non-
response in depressed patients (Eller et al., 2008). Yoshimura et al. 
(2009) found a correlation between high baseline levels of IL-6 
with refractory depression (Yoshimura et al., 2009). Therefore, it 
seems that suppression of pro-inflammatory cytokines may be nec-
essary for clinical recovery from depression and that reduction in 
inflammation might not happen in depressed patients who fail to 
respond to treatment.
Increased pro-inflammatory cytokines are known to induce 
acute phase (inflammatory) response in the liver, increasing the 
levels of CRP (Miller et al., 2009) and lower albumin and zinc in 
depression (Maes, 1995; Roomruangwong et al., 2016), suggesting 
that these could be useful biomarkers of depression. An interesting 
study conducted by Raison et al. (2013) tested if infliximab, a 
monoclonal antibody directed against TNF-α, would improve the 
mood of treatment-resistant depressive patients, since this pro-
inflammatory cytokine has been associated with depression and 
poor treatment response. The study randomized 60 medically 
healthy adults with treatment-resistant major depression, to either 
receive three infusions of infliximab (5 mg/kg) or three saline infu-
sions at baseline, week 2 and 6. Clinical assessments of depressive 
scores were made through HAM-D, the Clinical Global Impression 
– Severity scale, and inflammatory status (hs-CRP, and TNF and 
Table 3. Summary of clinical studies that assessed the anti-inflammatory effect of antidepressants on cytokines in MDD. The table describes the type 
and number of subjects investigated, antidepressant used, duration of treatment, cytokines assessed and final outcome of the study.
Author Type of patients Antidepressant(s) Duration Cytokines assessed Outcome
Brunoni et al. [2014] 103 unipolar depressive 
patients




Basterzi et al. [2005] 23 MDD and 23 controls Not specified (SSRI) 6 weeks IL-6 ↓IL-6
Eller et al. [2008] 100 MDD and 45 
controls
Escitalopram (SSRI) 12 weeks sIL-2R, IL-8, TNF-α ↓sIL-2R
Eller et al. [2009] 28 MDD and 45 controls Escitalopram + bupropion 
(SSRI + atypical AD)
6 weeks sIL-2R, IL-8, TNF-α ↑IL-8
Hernandez et al. [2008] 31 MDD and 22 controls Fluoxetine, paroxetine, 
sertraline (SSRI)
52 weeks IFN-γ, IL-1β, IL-2, IL-
4, IL-10, IL-13
↑IFN-γ, ↑IL-1β, ↓IL-2, 
↓IL-4, ↓IL-10, ↓IL-13
Lanquillon et al. [2000] 24 MDD and 15 controls Amitriptyline (TCA) 6 weeks IL-6, TNF-α ↓IL-6, ↓TNF-α
Piletz et al. [2009] 22 MDD and 17 controls Venlafaxine (SNRI) 8 weeks IL-1β, TNF-α No significant change
Sluzewska et al. [1995] 22 MDD and 11 controls Fluoxetine (SSRI) 8 weeks IL-6 ↓IL-6
Taraz et al. [2013] 50 MDD patients Sertraline (SSRI) 12 weeks IL-6, TNF-α, IL-10 ↓IL-6, ↓TNF-α, ↑IL-10
Tousoulis et al. [2009] 250 with HF  
(154 with MDD)
Not specified (SSRI and 
SNRI/TCA)
6 months IL-6, TNF-α SNRI/TCA: ↓TNF-α
Tuglu et al. [2003] 26 MDD and 17 controls Sertraline, fluoxetine, 
citalopram, fluvoxamine, 
paroxetine (SSRI)
6 weeks TNF-α ↓TNF-α
Vogelzangs et al. [2012] 1132 current depression; 
789 remitted 
depression; 494 controls
Not specified  
(SSRI, TCA and SNRI)
8 years IL-6, TNF-α SSRI: ↓IL-6
Yoshimura et al. [2009] 51 MDD and 30 controls Paroxetine, sertraline, 
fluvoxamine (SSRI); 
milnacipran (SNRI)
8 weeks IL-6, TNF-α ↓IL-6
AD, atypical antidepressant; HF, heart failure; IFN, interferon; IL, interleukin; MDD, major depressive disorder; sIL-2R, soluble interleukin-2 receptor; SNRI, serotonin and 
noradrenaline reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; TNF, tumor necrosis factor.
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its soluble receptors I and II), which were conducted at baseline 
and weeks 1, 2, 3, 4, 6, 8, 10 and 12. At the end of the trial (week 
12), neither differences in HAM-D score between groups, nor sig-
nificant interactions between treatment and time were found. A 
significant effect of time on decreased the HAM-D score was 
observed in both groups (p < 0.05). However, when analyzing 
baseline hs-CRP values to predict response to infliximab, a plasma 
hs-CRP concentration greater than 5mg/L was found to be the 
point at which infliximab-treated patients exhibited a greater 
decrease in HAM-D score than placebo patients (Raison et al., 
2013). The effect size of participants with hs-CRP levels higher 
than 5mg/L was 0.41, which is in line with the efficacy of antide-
pressants against placebo in most studies (Raison, 2016).
When selecting immunological biomarkers, one should take 
into consideration classical markers that already have standard-
ized assays for clinical application, such as CRP (Dantzer et al., 
2011), albumin and zinc. Pro- and anti-inflammatory cytokines 
should be determined when possible, even though the assays are 
not standardized yet and are more restricted to research trials. 
Ideally, the biomarkers should be measured through peripheral 
and central (CSF) samples.
Side effects of antidepressants
Despite all the aforementioned benefits of antidepressants, the 
treatment is not free from risks and side effects. In a study to 
assess self-discontinuation of antidepressants, 313 patients were 
interviewed to investigate the reason for stopping the treatment. 
Side effects were reported by 20% of the patients as the main 
cause of discontinuation (Samples and Mojtabai, 2015). 
Premature self-discontinuation is associated with relapse and 
incomplete response to the treatment. The key side effects associ-
ated with antidepressant use vary by class of the antidepressant 
and might vary also by medication within each class (Kemp, 
2014). Even though TCAs are very effective in treating depres-
sion, they also act on other receptor systems, including hista-
minic, cholinergic, adrenergic and postsynaptic serotonin 
receptors, leading to significant and sometimes intolerable side 
effects. Moreover, TCAs have a narrow therapeutic index and at 
higher doses, they might cause seizures and death due to slowing 
of intraventricular conduction, leading to complete heart block or 
ventricular re-entry arrhythmias (Ferguson, 2001). SSRIs, on the 
other hand, are better tolerated and significantly less toxic in an 
overdose than TCAs. The most common side effects related to 
SSRIs are gastrointestinal like nausea, activation syndrome, sex-
ual dysfunction, body weight gain, insomnia and serotonin syn-
drome (Miskovic, 2015). Antidepressants that also act on the 
noradrenergic system (i.e. SNRIs) are associated with signifi-
cantly greater increase in blood pressure and heart rate than 
SSRIs (Kemp, 2014) and also with gastrointestinal effects, acti-
vation syndrome, insomnia and sexual dysfunction (Miskovic, 
2015). In order to decrease self-discontinuation, it is important to 
choose an efficient antidepressant with the profile of side effects 




For those patients who fail to respond to the initial antidepressant 
therapy, alternative treatment approaches are switching medica-
tion, augmentation or combination therapies (Mendlewicz, 
2008). Augmentation strategies involve the usage of agents that 
are non-standard antidepressants to enhance the therapeutic 
effect of a known antidepressant (Akhondzadeh et al., 2009). 
Augmentation with COX-2 inhibitors such as celecoxib has been 
studied in clinical trials with promising results. For instance, a 
double-blind, randomized, placebo-controlled study was con-
ducted in 40 patients, using celecoxib + reboxetine (a norepi-
nephrine reuptake inhibitor) or placebo + reboxetine, as treatment 
for 6 weeks. A decrease of 55% in the HDRS score was observed 
after treatment with celecoxib + reboxetine, compared with a 
33% decrease after treatment with reboxetine + placebo. 
Interestingly, 45% of the patients in the celecoxib group showed 
complete remission after 6 weeks, compared with 20% in the pla-
cebo group (Müller et al., 2006). Abbasi et al. (2012) conducted 
a clinical trial assessing the cytokine profile and depressive 
symptoms in a group of patients treated with sertraline + 
celecoxib and in a group treated with sertraline + placebo; 40 
patients were randomly assigned to each group and the HDRS 
score as well as the levels of IL-6 were measured at baseline and 
after 6 weeks of treatment. At the end of week 6, the HDRS score 
was reduced by 96% in the celecoxib group compared with a 
50% reduction in the placebo group. Also, the IL-6 levels in 
serum were significantly more reduced in the celecoxib group 
compared with the placebo group (Abbasi et al., 2012). Celecoxib 
Figure 2. Possible anti-inflammatory mechanism of action of 
antidepressants. Antidepressants that increase the levels of serotonin 
(i.e. SSRIs) might exert their anti-inflammatory effects by cAMP-
mediated pathways. 5-HT increases intracellular cAMP levels via 5-HT 
receptors linked to G protein-mediated stimulation of adenylyl cyclase, 
leading to a reduction in the expression of cytokines via inhibition of 
the protein kinase A (PKA) pathway.
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was also successfully used in a 6-week combination treatment 
with another SSRI, fluoxetine, in 40 depressive patients. The 
combination of celecoxib with fluoxetine was able to reduce the 
HDRS score with 90%, while placebo + fluoxetine reduced only 
50% (Akhondzadeh et al., 2009).
Since the add-on strategy with NSAIDs, mainly celecoxib, 
could be a potentially effective augmentation, a meta-analysis of 
the data from randomized clinical trials was performed by three 
authors. Faridhosseini et al. (2014) analyzed data from four ran-
domized clinical trials that used celecoxib as augmentation ther-
apy for unipolar depression (n = 160 patients). Celecoxib or 
placebo was used in combination with sertraline, reboxetine or 
fluoxetine and the effect on HDRS score was evaluated. The 
pooled OR of treatment response of celecoxib vs placebo was 
6.6, 95% CI = 2.5–17, p < 0.0001; pooled OR of remission 
response was 6.6, 95% CI = 2.7–15.9, p < 0.0001; pooled OR in 
means of HDRS score decrease at week 6 was 3.43, 95% CI = 
1.9–4.9, p < 0.0001. In summary, celecoxib in a daily dose of 400 
mg/day as an add-on therapy to antidepressants is effective in 
MDD. No adverse effects attributable to celecoxib were observed 
(Faridhosseini et al., 2014). Köhler et al. (2014) included 10 ran-
domized clinical trials, from which only 4 were add-on therapy 
with NSAID (i.e. celecoxib) or placebo with an SSRI or SNRI. A 
significant improvement in depressive symptoms was observed 
when compared with placebo in four trials (n = 132); standard-
ized mean difference (SMD) was −0.82, 95% CI = −1.17 to 
−0.46, p < 0.001). In addition, add-on treatment improved remis-
sion with OR 7.89, 95% CI = 2.94–21.17, p < 0.001 and response 
(three trials, n = 92 patients) with OR 6.59, 95% CI = 2.24–19.42, 
p < 0.001). No evidence of increased gastrointestinal or cardio-
vascular adverse effects was reported; the length of trials ranged 
from 6–8 weeks (Köhler et al., 2014). Rosenblat et al. (2016) 
preformed a meta-analysis on data from randomized clinical tri-
als focused on bipolar depression. Only two studies used NSAIDs 
(aspirin or celecoxib) and compared the efficacy with placebo (n 
= 53). Pooled effects size revealed an SMD of 0.02, 95% CI = 
−0.52–0.56, p > 0.05. Add-on treatment strategy had no signifi-
cant difference in depressive symptoms (HDRS) or young mania 
rating scale (YMRS). This result might be attributable to the 
low level of add-on NSAID studies in bipolar disorder and there-
fore, it might be underpowered and less robust than other meta-
analyses (Rosenblat et al., 2016).
Based on these data, it seems that adjuvant treatment with 
COX-2 inhibitors might be a good strategy to improve respon-
siveness of unipolar depressive patients. Even though the clinical 
studies performed until now focused mainly on the reduction of 
depressive symptoms as the outcome parameter, effects of treat-
ment on immunological biomarkers (e.g. cytokines, CRP) should 
be an outcome parameter as well, especially when SSRIs and 
NSAID combination treatment is applied. More clinical studies 
with larger samples size and improved study design should be 
conducted in order to have more substantial evidence for the 
additional efficacy of add-on NSAID treatment.
Moreover, when assessing the adverse effects of add-on NSAID 
treatment in the reported trials, no relevant adverse effects were 
found. This might be attributable to the short treatment period 
that ranged from 6–8 weeks. This period might be too short to 
identify any adverse effects. Recently, a study was performed on a 
Korean population to investigate the risk of intracranial hemor-
rhage among patients treated either with the combination of 
antidepressants and NSAIDs (n = 2,072,613) or antidepressants 
alone (n = 2,072,613), during a 30-day follow up after the first 
antidepressant prescription. An increased risk of intracranial hem-
orrhage was found when combined therapy was used (hazard ratio 
1.6, 95% CI = 1.32–1.85). The risk of intracranial hemorrhage was 
greater in men than women (2.6, 95% CI =1.93–3.42 vs 1.2, CI 
95% = 0.89–1.57). No significant difference was found between 
antidepressant classes (Shin et al., 2015). Even though the study 
provides alarming data, further research is required to replicate the 
data in different ethnic groups. No explanation was given concern-
ing the higher risks in men than women, or if the risk increases 
with aging. Another study by Bak et al. (2002) was conducted to 
investigate association of SSRI usage with ischemic stroke or 
intracerebral hemorrhage, since previous published data demon-
strated that SSRI attenuated platelet activation and decreased the 
risk of thromboembolism formation (Chu et al., 2016). The results 
suggest that SSRIs are not a risk factor for intracerebral hemor-
rhage and are probably not associated with decreased risk of 
ischemic stroke. In a secondary analysis, an investigation of cur-
rent associations of SSRI and NSAIDs, only five events of intrac-
erebral hemorrhage were described among 659 total intracerebral 
hemorrhage events (Bak et al., 2002). Nevertheless, in primary 
psychiatric care, caution must be taken when prescribing antide-
pressants for current NSAID users with other associated risk fac-
tors (e.g. anti-platelet aggregation therapy).
Non-pharmacological anti-inflammatory 
strategies
Non-pharmacologic augmentation strategies such as exercise and 
mind–body therapies (MBTs) have demonstrated anti-inflammatory 
effects in several diseases, such as heart failure (Pullen et al., 
2008) and depression (Lavretsky et al., 2011). MBTs include 
meditation, yoga, progressive relaxation and Tai Chi. (Muehsam 
et al., 2017). These practices have been described as able to regu-
late emotional and affective response to stress and therefore, 
influence the immune system. A meta-analysis conducted by 
Morgan et al. (2014) demonstrated a significant effect of MBTs in 
decreasing CRP as compared with controls (Morgan et al., 2014). 
Evidence also suggests that regular endurance exercise decreases 
inflammatory markers, mainly CRP (Haaland et al., 2008). 
Although MBTs and exercise are non-pharmacological augmenta-
tive strategies, both are able to decrease stress levels and modulate 
immunity, increasing the quality of life of MDD patients.
Besides MBTs other lifestyle changes, such as dietary inter-
ventions, could have a beneficial effect on depression as well. 
For example, nutraceuticals like zinc and omega-3 fatty acids 
were shown to have beneficial effects on depression (Sarris et al., 
2016). These nutrients may exert their effect by interaction with 
inflammatory pathways (Johnson, 2015).
Concluding remarks
Several theories are available to explain the pathophysiology of 
MDD, mainly focusing on the involvement of environmental fac-
tors associated with genetic and biochemical components (Maciel 
et al., 2013). Inflammatory deregulation as an etiological factor 
appears to be a plausible hypothesis to explain why 30–50% of 
the depressive patients do not respond to conventional therapy. 
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The presence of continuous stimuli that increase the levels of 
pro-inflammatory cytokines in the brain can cause neurotrans-
mitter imbalance, neuroinflammation and neurodegeneration. 
Intervention in this process could be an important aim to prevent 
further damage in the CNS. The levels of inflammatory biomark-
ers, mainly IL-1β, IL-6, TNF-α and hs-CRP in the serum of 
depressed patients could be useful biomarkers, along with evalu-
ation of depressive scores. This assessment would be important 
to guide physicians in patients’ classification (e.g. depression 
with elevated immune profile), selection of the best treatment to 
be applied and as an indicator of possible treatment resistance to 
conventional antidepressant drugs.
Concerning treatment, SSRIs were shown to have an anti-
inflammatory effect in clinical trials, as they proved potent agents 
able to decrease the levels of pro-inflammatory cytokines and to 
diminish depressive symptoms in a subset of patients. Another 
benefit regarding the usage of SSRI is their higher tolerability in 
patients. More studies need to be conducted to further elucidate the 
anti-inflammatory mechanism action of SSRIs and other classes of 
antidepressants, such as TCAs. Imipramine in particular, shows an 
interesting effect in vitro and in pre-clinical studies; besides 
decreasing the pro-inflammatory cytokines, it prevented morpho-
logical changes and activation of microglia, thus limiting neuroin-
flammation. This effect might be useful to prevent further 
neurodegeneration associated with chronic activation of microglia 
not only in MDD, but in other CNS diseases associated with neu-
roinflammation. In general, the best results seem to be obtained 
with the combination of antidepressants with NSAIDs when initial 
antidepressant therapy fails (i.e. augmentative therapy). NSAIDs 
alone have shown best antidepressant results when administered as 
curative treatment to patients with an inflammatory comorbidity.
Even though considerable lines of research support the immu-
nological hypothesis of depression, the main treatment targets 
have remained limited to the monoaminergic system. This is 
mainly due to the fact that the evidence for successful treatment 
of MDD with anti-inflammatories is still insufficient to adapt 
treatment guidelines for the subgroup of depressed patients with 
increased cytokine levels. In the present review, we have sum-
marized the evidence for the benefits of anti-inflammatory treat-
ment for MDD, either as single treatment or as augmentative 
therapy, and highlighted the anti-inflammatory effect that some 
antidepressants exert by themselves. However, before anti-
inflammatory therapies for MDD can be applied in regular 
patient care, prospective studies on the efficacy of the anti-
inflammatory treatment that combine the evaluation of depres-
sive symptoms with quantification of inflammatory biomarkers 
are much needed. With substantial proof of efficacy, these alter-
native approaches can be applied in patient-tailored therapy-
selection strategies, thus striving for an improved quality of life, 
especially for depressive patients with an immunological deregu-
lation profile and treatment resistance to conventional therapy.
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